AU2001280597A1 - Compositions for sustained release of analgesic agents, and methods of making and using the same - Google Patents

Compositions for sustained release of analgesic agents, and methods of making and using the same

Info

Publication number
AU2001280597A1
AU2001280597A1 AU2001280597A AU8059701A AU2001280597A1 AU 2001280597 A1 AU2001280597 A1 AU 2001280597A1 AU 2001280597 A AU2001280597 A AU 2001280597A AU 8059701 A AU8059701 A AU 8059701A AU 2001280597 A1 AU2001280597 A1 AU 2001280597A1
Authority
AU
Australia
Prior art keywords
compositions
making
methods
same
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280597A
Inventor
Wenbin Dang
Stephen Dordunoo
Abdul Kader
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Corp of North America
Original Assignee
Guilford Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharmaceuticals Inc filed Critical Guilford Pharmaceuticals Inc
Publication of AU2001280597A1 publication Critical patent/AU2001280597A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/605—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
AU2001280597A 2000-07-17 2001-07-17 Compositions for sustained release of analgesic agents, and methods of making and using the same Abandoned AU2001280597A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21862900P 2000-07-17 2000-07-17
US60/218,629 2000-07-17
PCT/US2001/022525 WO2002005800A2 (en) 2000-07-17 2001-07-17 Compositions for sustained release of analgesic agents, and methods of making and using the same

Publications (1)

Publication Number Publication Date
AU2001280597A1 true AU2001280597A1 (en) 2002-01-30

Family

ID=22815846

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280597A Abandoned AU2001280597A1 (en) 2000-07-17 2001-07-17 Compositions for sustained release of analgesic agents, and methods of making and using the same

Country Status (3)

Country Link
US (1) US20020045668A1 (en)
AU (1) AU2001280597A1 (en)
WO (1) WO2002005800A2 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10028851B2 (en) * 1997-04-15 2018-07-24 Advanced Cardiovascular Systems, Inc. Coatings for controlling erosion of a substrate of an implantable medical device
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
WO2002030472A2 (en) * 2000-10-12 2002-04-18 Guilford Pharmaceuticals, Inc. Compositions for release of radiosensitizers, and methods of making and using the same
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
US20080182841A1 (en) * 2001-10-29 2008-07-31 Levine Howard L Vaginally administered anti-dysrhythmic agents for treating pelvic pain
US7829109B2 (en) * 2001-11-14 2010-11-09 Durect Corporation Catheter injectable depot compositions and uses thereof
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
AU2003216424A1 (en) * 2002-02-25 2003-10-08 Guilford Pharmaceuticals, Inc. Phosphorus-containing compounds with polymeric chains, and methods of making and using the same
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
MXPA05001244A (en) * 2002-07-31 2005-06-08 Alza Corp Injectable multimodal polymer depot compositions and uses thereof.
WO2004012703A1 (en) * 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
GB0218830D0 (en) * 2002-08-13 2002-09-18 Syngenix Ltd Anaesthetic conjugate
US7220271B2 (en) * 2003-01-30 2007-05-22 Ev3 Inc. Embolic filters having multiple layers and controlled pore size
US7323001B2 (en) * 2003-01-30 2008-01-29 Ev3 Inc. Embolic filters with controlled pore size
US20050131513A1 (en) * 2003-12-16 2005-06-16 Cook Incorporated Stent catheter with a permanently affixed conductor
US8403923B2 (en) * 2004-10-29 2013-03-26 Spinal Restoration, Inc. Injection of fibrin sealant in the absence of corticosteroids in spinal applications
US8206448B2 (en) 2004-10-29 2012-06-26 Spinal Restoration, Inc. Injection of fibrin sealant using reconstituted components in spinal applications
US7597687B2 (en) * 2004-10-29 2009-10-06 Spinal Restoration, Inc. Injection of fibrin sealant including an anesthetic in spinal applications
US8419722B2 (en) * 2004-10-29 2013-04-16 Spinal Restoration, Inc. Apparatus and method for injection of fibrin sealant in spinal applications
US20110213464A1 (en) * 2004-10-29 2011-09-01 Whitlock Steven I Injection of fibrin sealant in the absence of corticosteroids in spinal applications
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
EP1909762A2 (en) * 2005-07-28 2008-04-16 Isp Investments Inc. Amorphous efavirenz and the production thereof
WO2007134239A2 (en) * 2006-05-12 2007-11-22 Cordis Corporation Balloon expandable bioabsorbable drug eluting flexible stent
CA2652753C (en) * 2006-05-12 2015-12-08 Cordis Corporation Balloon expandable bioabsorbable drug eluting stent
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
EP2125938A2 (en) 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
EP2144599B1 (en) * 2007-03-02 2010-08-04 Farnam Companies, Inc. Sustained release pellets comprising wax-like material
USRE46397E1 (en) * 2007-11-07 2017-05-09 Svip5 Llc Slow release of organic salts of local anesthetics for pain relief
US7972373B2 (en) * 2007-12-19 2011-07-05 Advanced Technologies And Regenerative Medicine, Llc Balloon expandable bioabsorbable stent with a single stress concentration region interconnecting adjacent struts
WO2010011466A2 (en) * 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
CN102481438B (en) * 2009-06-26 2013-09-18 塔里斯生物医药公司 Implantable drug delivery devices and methods of making the same
US9017312B2 (en) 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
US20140074012A1 (en) * 2012-09-13 2014-03-13 Ernesto Andrade Composition, system and method for tissue augmentation
CN103601650B (en) * 2013-01-16 2014-08-06 四川大学华西医院 N-diethylaminoacetyl-2,6-dimethylaniline derivatives, preparation method and applications thereof
BR112015022433B1 (en) 2013-03-15 2022-06-21 Taris Biomedical Llc Intravesical drug delivery device
CN113413393A (en) 2013-08-19 2021-09-21 塔里斯生物医药公司 Multi-unit drug delivery device and method
CA2931547A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
EP3285850A1 (en) 2015-04-23 2018-02-28 TARIS Biomedical LLC Drug delivery devices with drug-permeable component and methods
WO2019032541A1 (en) * 2017-08-07 2019-02-14 The University Of Akron Poly(ester urea)s for shape memory and drug delivery
CN115666621A (en) 2020-01-13 2023-01-31 度勒科特公司 Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5099030A (en) * 1987-03-09 1992-03-24 The Procter & Gamble Company Novel compounds, pharmaceutical compositions, and methods for treating inflammation and pain
EP0973818B1 (en) * 1997-04-03 2004-10-13 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making and using the same
UA54505C2 (en) * 1997-04-03 2003-03-17 Гілфорд Фармасьютікалз Інк. Biodegradable polymers, bound by phosphates, compositions, products and pocesses for manufacturing and using thereof
KR20010020432A (en) * 1997-04-30 2001-03-15 토마스 씨. 서 Biodegradable compositions comprising poly(cycloaliphatic phosphoester) compounds, articles, and methods for using the same
US6153212A (en) * 1998-10-02 2000-11-28 Guilford Pharmaceuticals Inc. Biodegradable terephthalate polyester-poly (phosphonate) compositions, articles, and methods of using the same
US6350464B1 (en) * 1999-01-11 2002-02-26 Guilford Pharmaceuticals, Inc. Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same
US6537585B1 (en) * 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
WO2002030472A2 (en) * 2000-10-12 2002-04-18 Guilford Pharmaceuticals, Inc. Compositions for release of radiosensitizers, and methods of making and using the same
WO2003007915A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Compositions for treatment of head and neck cancers, and methods of making and using the same
WO2003007914A2 (en) * 2001-07-19 2003-01-30 Guilford Pharmaceuticals, Inc. Biocompatible polymer containing composition for treatment of prostate cancers

Also Published As

Publication number Publication date
WO2002005800A3 (en) 2002-10-31
WO2002005800A2 (en) 2002-01-24
WO2002005800A9 (en) 2003-08-28
US20020045668A1 (en) 2002-04-18
WO2002005800A8 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU2001280597A1 (en) Compositions for sustained release of analgesic agents, and methods of making and using the same
AU2002243277A1 (en) Methods and compositions for encapsulating active agents
AU2001294814A1 (en) Pumpcn compositions and uses thereof
AU2001291222A1 (en) Wax-modified thermosettable compositions
AU2001285143A1 (en) Methods and compositions for targeted delivery
AU2002229140A1 (en) Controlled release pharmaceutical composition
AU2001236457A1 (en) Compounds and compositions for delivering active agents
AU2001280604A1 (en) Compositions comprising icariside i and anhydroicaritin and methods for making the same
AU2001230902A1 (en) Slow-release insect-repellent composition and uses
AU2001284985A1 (en) Compounds and compositions for delivering active agents
AU2002214284A1 (en) Anti-helicobacterial agents
AUPR602501A0 (en) Sustained release pharmaceutical composition
AU2001264264A1 (en) Sustained release compositions
AU2001288277A1 (en) Compounds and compositions for delivering active agents
AU2001290239A1 (en) Medicinal composition
AU2001248772A1 (en) Sustained release drug compositions
AU2002215333A1 (en) Compositions for release of radiosensitizers, and methods of making and using the same
AU2001241098A1 (en) Composition
AU2001246861A1 (en) Sustained release preparations
AU2001270310A1 (en) Compositions for sustained release of antineoplastic taxanes, and methods of making and using the same
AU2002226047A1 (en) Release agent composition
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
AU2001287852A1 (en) Composition
AU2001232075A1 (en) Compound, composition and use
AU2002365136A1 (en) Compositions and methods for controlled release